key: cord-0833710-4ot7gif8 authors: Alvarez-Mon, M.; Asunsolo, A.; Sanz, J.; Munoz, B.; Arranz-Caso, J. A.; Novella Mena, M.; Hernandez-Gutierrez, C.; Navarro, J.; Lozano Duran, M. C.; Arevalo Serrano, J.; Heche Sanchez, R.; Bravo Quiroga, L.; Flores Segovia, J.; Garcia Sanchez, M.; Gutierrez Garcia, A.; Perez, A.; Herrero, M.; Plana, N.; Troncoso, D.; Rackov, G.; Martinez-A, C.; Balomenos, D. title: Tocilizumab efficacy in COVID-19 patients is associated with respiratory severity-based stages date: 2021-03-09 journal: nan DOI: 10.1101/2021.03.04.21252167 sha: 7554d3ddd2e6e1e5f24587f9eed00dd6c42346b5 doc_id: 833710 cord_uid: 4ot7gif8 Background: Tocilizumab treatment is investigated, and effectiveness in ICU-admitted COVID-19 patients has been reported. Although controversy exists regarding the efficacy of tocilizumab treatment, it has been suggested that tocilizumab might show positive results depending on patient severity status. We examined an association between tocilizumab and distinct disease severity stages. Methods and Findings: From March 3 to March 23 2020, 494 consecutively admitted COVID-19 patients received tocilizumab or standard treatment alone. Data were obtained retrospectively. Clinical respiratory severity (CRS) stages were defined by patient oxygenation status and were also associated to scores of WHO clinical progression scale. We categorized patients in three stages, mild/moderate CRS1 (FiSpO2<0.35; WHO score 5), moderate/severe CRS2 (FiO2=0.5/high flow mask; WHO score 6) and severe/critical CRS3 (FiO2<80%/high flow/prone position or mechanical ventilation; score>6). The primary outcome was the composite of death or ICU admission in patients of stages CRS1, CRS2, and CRS3, as well as in total patients. We also addressed mortality alone in total patients. Kaplan-Maier curves, Cox proportional regression and inverse probability weighting marginal structural models were used. We conducted the study from March 3 to April 7 2020 with broad-ranged severity patients; 167 tocilizumab-treated and 327 untreated. CRS1 patients showed no apparent benefit after treatment, while the risk of the primary outcome was greatly reduced in CRS2 treated participants ((HR=0.22; 95% CI (0.16-0.44)). Moreover, tocilizumab treatment was associated with significantly decreased CRS2 patient proportion that reached the outcome compared to non-treated controls (27.8.0% vs. 65.4%; p<0.001). Severe/critical CRS3 patients, also showed benefit after treatment (HR=0.38; 95% CI (0.16-90)), although not as robust as was that of CRS2 treated individuals. Tocilizumab was associated with reduced outcome risk in total patients (HR=0.42; 95% CI (0.26-0.66)) after CRS adjustment, but not if CRS classification was not accounted as confounding factor (HR=1.19; 95% CI (0.84-1.69)). The outcome of mortality alone upon tocilizumab treatment was significant (HR=0.58; 95% CI (0.35-0.96)) after accounting for CRS classification. Conclusions: Tocilizumab treatment is associated with reduced COVID-19 escalation in CRS2 patients, suggesting efficacy in moderate/severe non-ICU-admitted patients. CRS classification could represent an essential confounding factor in evaluating tocilizumab in studies of broad-ranged severity patients. 4 but not if CRS classification was not accounted as confounding factor (HR=1.19; 95% CI (0.84-1.69)). The outcome of mortality alone upon tocilizumab treatment was significant (HR=0.58; 95% CI (0.35-0.96)) after accounting for CRS classification. Conclusions: Tocilizumab treatment is associated with reduced COVID-19 escalation in CRS2 patients, suggesting efficacy in moderate/severe non-ICU-admitted patients. CRS classification could represent an essential confounding factor in evaluating tocilizumab in studies of broad-ranged severity patients. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint INTRODUCTION 1 severely ill patients [24] , while the RECOVERY trial demonstrated that tocilizumab reduces 23 mortality in patients receiving corticosteroids [25] . Recent meta-analysis found an association 24 between tocilizumab and improved outcomes in moderate and severe patients (non-ICU), as 25 well as in critically ill patients (ICU) [26] . 26 We conducted a retrospective cohort study of 494 consecutively admitted COVID-19 27 patients that were classified in stages according to their Clinical Respiratory Severity (CRS). 28 We provide evidence that tocilizumab is associated with reduced disease escalation in a CRS-29 depending manner, and that CRS classification is a critical confounding factor to be 30 accounted for upon evaluation of tocilizumab's therapeutic potential in the global patient 31 population. 32 33 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint Patients 36 Patients positive for SARS-Cov-2 from March 3 to March 23 2020 who met the 37 conditions of (1) respiratory rate ≥ 30 breaths/min, (2) SpO 2 ≤ 94% while breathing ambient 38 air, and (3) thorax X-ray with opacities, were included in the study, as defined by the 39 Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (6th interim edition) 40 [27] . 41 We obtained demographic data, as well as comorbidities (cancer, diabetes mellitus, 42 cardiovascular disease, chronic kidney disease, among others) from electronic health records. 43 We registered clinical symptoms, time of disease onset and laboratory and radiological data. 44 Standard treatment (ST) included lopinavir/ritonavir, hydroxychloroquine, IFN-β and 45 azithromycin in case of secondary infections (Supplementary Table 1 ). IFNβ administration 46 depended on the comorbidity extent and on age (> 65 years old). Two doses of IFNβ (at 47 admission and at 48 h, discontinued then after due to apparent patient worsening) were given 48 to 89 tocilizumab-treated patients and to 90 controls. At admission, patients received oxygen 49 support though low-flow nasal cannula to maintain SpO 2 >90%. Patients with increased 50 oxygen needs were switched to high-flow oxygen mask (Venturi mask up to 50% FiO 2 ). 51 Mechanical ventilation (MV) was provided only to ICU admitted patients. Considering the 52 critical situation at the hospital, access to ICU was limited and patients that would otherwise 53 be admitted to ICU were treated on the ward. 54 Patient selection for tocilizumab treatment depended on the study design, the availability 58 of tocilizumab and on ethical decisions, based on patient evolution during the time between 59 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Initially, patient severity was considered on the basis of SpO 2 measurements on ambient 80 air and/or after low-flow oxygen supply during initial observation (24 hours or less). The 81 groups were defined by patients with SpO 2 >90% (corresponding to CRS1), 80%90% predicted survival, while SpO 2 <90% 206 levels were associated with COVID-19 escalation [42] . Results obtained during the study, 207 such as CRP levels, SpO 2 /FiO 2 and estimated PaO 2 /FiO 2 ratios further validated CRS stage 208 classification and corroborated the stage severity CRS1< CRS2< CRS3. Further refining of 209 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. When global patient population was considered, three models of regression analysis 232 showed that tocilizumab was associated with a reduced risk of the composite outcome, after 233 accounting for CRS stage classification as a confounding factor together with patient age, sex 234 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. Our study has the following limitations. First, the study was performed in one hospital and 254 was not randomized as tocilizumab treatment was prioritized for worsening patients within 255 the same CRS stage. Second, CRS3 stage patient population did not get the support of MV 256 due to the near collapse conditions in Spain at the time of the study. Third, our study was not 257 blinded and therefore a bias for ICU admission could favor untreated patients; this limitation 258 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint was minimized as analysis of overall hospital mortality as an endpoint showed benefit after 259 tocilizumab treatment. 260 The strengths of this study include the newly applied patient classification in CRS stages. 261 This later point is crucial since previous studies mostly found no tocilizumab effect when 262 considering patients of wide range disease severity. Several analyses were performed, with 263 consistent results across the models. Oxygen supplementation was uniform especially for the 264 CRS2 stage, as the vast majority of the patients were managed on the floor (i.e. not in the 265 ICU) on steady FiO 2 , avoiding the bias of oxygen supplementation in influencing the 266 outcome. Finally, although differences in tocilizumab efficacy have been suggested to depend 267 on disease stage, here we show this in a single study that encompassed three disease stages. 268 Tocilizumab shows variable efficacy, depending on three COVID-19 clinical respiratory 270 severity (CRS) stages. Treatment had no apparent benefit in CRS1 patients, but was 271 associated with a remarkable benefit in CRS2 patients, suggesting that tocilizumab could 272 target stages that did not require ICU care. These findings could contribute to define the 273 optimal point for treatment initiation. In general terms, our results indicate that the CRS-274 associated efficacy of tocilizumab could eventually hinder evaluation of its therapeutic effect, 275 and suggest the possibility to consider CRS patient classification as a confounding factor in 276 analyzing the efficacy of tocilizumab. These conclusions could assist in designing and/or 277 interpreting randomized clinical trials. 278 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. Tocilizumab discontinuation after attaining remission in patients with rheumatoid 302 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 9, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint Figure 3 A B . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted March 9, 2021. ; https://doi.org/10.1101/2021.03.04.21252167 doi: medRxiv preprint Estimating 279 clinical severity of COVID-19 from the transmission dynamics in Wuhan Coronavirus disease 2019 (COVID-19): a clinical update Clinical course and risk factors for 284 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort 285 study Patients Hospitalized with Covid-19 Pneumonia Interleukin-6 Receptor Antagonists in Critically Ill Patients with 359 RECOVERY Collaborative Group COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, 363 platform trial Comparative efficacy and safety of 366 pharmacological interventions for the treatment of COVID-19: A systematic review 367 and network meta-analysis Characteristics IE. Diagnosis and Treatment Protocol for Novel Coronavirus 370 Pneumonia (Trial Version 6, Revised) A minimal 372 common outcome measure set for COVID-19 clinical research Acute respiratory distress syndrome: The Berlin definition of SpO2/FiO2serves as a noninvasive prognostic marker for intensive care patients 408 with COVID-19 Hypoxemia and Mortality in Patients With COVID-19 Time to Reassess Tocilizumab's Role in COVID-19 Pneumonia COVACTA trial raises questions about tocilizumab's benefit in COVID-19 Between Early Treatment With Tocilizumab and Mortality Among Critically Ill 418 Patients With COVID-19 Tocilizumab in patients with severe COVID-19: a retrospective cohort study